Quincey James 4

What Happened
Quincey James, a member of Pfizer Inc.'s Board of Directors, was granted 1,433.062 phantom share units on 2026-03-27. The units are reported at a grant price/value of $27.04 each, for a total reported value of $38,750. This was an award/derivative grant (transaction code A) representing deferred director compensation, not an open-market purchase or sale.

Key Details

• Transaction date: 2026-03-27; filing date: 2026-03-30 (filed within SEC timing requirements).
• Quantity and price: 1,433.062 units @ $27.04 each; total value $38,750.
• Shares owned after transaction: Not specified in the filing.
• Footnotes:
  • Each unit represents one phantom share of common stock. (F1)
  • Units are deferred director compensation (including dividend equivalents) and will be settled in cash or common stock at the director’s election following retirement from the Board. (F2)
• Transaction type: Award/grant of a derivative (phantom share) — coded "A".

Context
These are deferred compensation units (phantom shares), meaning they are not immediate stock purchases; they will be paid out in cash or stock later, typically upon retirement. Such grants are routine for non-employee directors and do not by themselves indicate the director is buying or selling shares on the open market.